Diabetes

Yoga for Glycemic Control in Low-Income Women with Type 2 Diabetes: RCT Results

A 12-week RCT finds structured yoga improves fasting glucose, HbA1c, and self-care in low-income women with type 2 diabetes, though the glycaemic effect exceeds typical yoga trials. PICO summary and commentary.

How Does Empagliflozin Affect Heart Failure in Type 2 Diabetes Patients?

A small biomarker RCT finds empagliflozin reduces the renal tubular marker KIM-1 in diabetic heart failure with preserved ejection fraction, with no effect on other biomarkers. PICO summary and commentary.

Metformin Does Not Improve Insulin Resistance in Type 1 Diabetes: A Negative Trial

A 26-week double-blind RCT finds metformin does not reduce insulin resistance in adults with type 1 diabetes, with no change in endogenous glucose production versus placebo. PICO summary and commentary.

Can tibial nerve techniques enhance pain management for diabetic neuropathy?

A sham-controlled trial finds adding tibial nerve neurodynamic techniques to standard care reduces neuropathy severity and improves quality of life in diabetic neuropathy, though nerve conduction is unchanged. PICO summary and commentary.

How do DPP-4 inhibitors and bedtime NPH insulin affect microRNAs in type 2 diabetes?

A small RCT finds adding sitagliptin or bedtime NPH insulin lowers HbA1c similarly in type 2 diabetes but produces distinct microRNA changes, with sitagliptin affecting a broader set. PICO summary and commentary.

Hyaluronan-Minocycline Gel as Adjunct to Scaling in Diabetic Periodontitis: Split-Mouth RCT

Bedtime Snacking and Nocturnal Glycemia in Young Children with Type 1 Diabetes: Crossover RCT

Does vonoprazan reduce proteinuria in diabetic kidney disease?

An RCT finds vonoprazan reduces albuminuria and improves eGFR more than lansoprazole in diabetic kidney disease, independent of H. pylori status, suggesting a possible direct renal effect. PICO summary and commentary.

Does Adding Empagliflozin Improve Peripheral Neuropathy in Type II Diabetes?

A 20-week RCT finds adding empagliflozin improves glucose, kidney function, neuropathy symptoms, and nerve conduction velocity in type 2 diabetes, though amplitude and exam scores were unchanged. PICO summary and commentary.

Did adding sitagliptin to metformin improve outcomes for type 2 diabetes patients?

A 12-week RCT finds adding sitagliptin to metformin improves fasting glucose, lipids, beta-cell function, and inflammatory cytokines, though HbA1c did not change significantly. PICO summary and commentary.